CD177 and glioblastoma: This virus shares different capsid modifications with the reported oncolytic adenovirus for glioblastoma therapy, and is capable to infect cells via three types of receptors (CAR, SA, and TRAILRs), resulting in the advantages of A4/K37 to enter and kill heterogeneous glioma cells with the non-uniform expression of cell surface receptors, although further studies using patients' glioblastoma tissues in vitro and in patient-derived tumor xenograft (PDX) mouse models are warranted (Supplementary Table).